CMS Off-Label Cancer Drug Policy Will Have "Very Narrow" Focus
This article was originally published in The Pink Sheet Daily
Executive Summary
Policy decision for covering unapproved, non-compendial indications for cancer drugs is still pending, but will not mean a "sea change" in reimbursement, agency official says. Real issue is "unorganized" approach to off-label use as a whole in the U.S.
You may also be interested in...
Medicare Part B Oral Chemotherapy Demo To Cover Tamoxifen and Thalidomide
In announcing the start of the demonstration project, CMS departs from earlier demo criteria by saying that tamoxifen qualifies as a “replacement” drug and thalidomide is covered because it has a pending supplemental NDA for an indication qualifying it for the project.
Medicare Part B Oral Chemotherapy Demo To Cover Tamoxifen and Thalidomide
In announcing the start of the demonstration project, CMS departs from earlier demo criteria by saying that tamoxifen qualifies as a “replacement” drug and thalidomide is covered because it has a pending supplemental NDA for an indication qualifying it for the project.
NCI/CMS Group Will Examine Coverage For Off-Label Cancer Drug Use
The collaboration between the National Cancer Institute and Centers for Medicare & Medicaid Services will work to formulate a policy that may be useful for commercial health insurance coverage of drugs, an NCI rep says.